Koers Medipharm Labs Corp Toronto S.E.
Aandelen
CA58504D1006
Farmaceutische producten
Omzet 2024 * | 42 mln. 30,8 mln. 28,37 mln. | Omzet 2025 * | 54,91 mln. 40,27 mln. 37,09 mln. | Marktkapitalisatie | 32,34 mln. 23,71 mln. 21,84 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -9 mln. -6,6 mln. -6,08 mln. | Nettowinst (verlies) 2025 * | -2 mln. -1,47 mln. -1,35 mln. | EV/omzet 2024 * | 0,77 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,59 x |
K/w-verhouding 2024 * |
-4
x | K/w-verhouding 2025 * |
-16
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,53% |
Recentste transcriptie over Medipharm Labs Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Greg Hunter
DFI | Director of Finance/CFO | - | 08-02-21 |
Keith Strachan
PSD | President | - | 01-10-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 01-04-23 |
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Shelley Martin
BRD | Director/Board Member | - | 22-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,06% | 6,19 mld. | |
-15,95% | 4,48 mld. | |
+6,36% | 3,29 mld. | |
-11,34% | 3,12 mld. | |
-3,12% | 2,5 mld. | |
+45,41% | 1,94 mld. | |
-7,74% | 1,68 mld. | |
-0,67% | 1,64 mld. | |
-11,32% | 1,56 mld. |